Apothecary Pharma GLP-1 Injection Recall, All 22 Tirzepatide Lots and the NAD+ Vial

Apothecary Pharma LLC is recalling 23 vials of compounded injectable drugs nationwide because it cannot assure their sterility. The recall covers 22 vials of compounded tirzepatide injection and one vial of NAD+ injection. The company started the voluntary recall on September 24, 2026, and the FDA classified it as Class II on October 8, 2026.

The tirzepatide is an 18 mg/mL prescription injection in a 4 mL multidose vial, NDC 85091-001-18. The affected lots are AP-202622 through AP-202625 and AP-202627 through AP-202644. Lot AP-202626 is not part of the recall. The NAD+ injection is a 200 mg/mL product in a 6 mL multidose vial, NDC 85091-011-06, lot AP-202647.

This is not a recall of all GLP-1 drugs. The notice does not list FDA-approved Mounjaro, Zepbound, Ozempic or Wegovy. NAD+ is not a GLP-1 medication, but it is part of the same recall.

If your vial matches a recalled lot, do not inject from it. Contact your prescriber or pharmacist for instructions. If you already used an affected vial and develop fever, redness, swelling or worsening pain at the injection site, get medical advice promptly.

Apothecary Pharma Recall: Quick Facts

Detail	Official information
Company	Apothecary Pharma LLC (Cary, North Carolina)
Recall type	Voluntary nationwide drug recall
Recall initiated	September 24, 2026
FDA classification	Class II, October 8, 2026
Total vials recalled	23 (22 tirzepatide + 1 NAD+)
Reason	Lack of assurance of sterility
Tirzepatide	18 mg/mL, 4 mL multidose vial, NDC 85091-001-18
Tirzepatide lots	AP-202622 to AP-202625 and AP-202627 to AP-202644
NAD+	200 mg/mL, 6 mL multidose vial, NDC 85091-011-06, lot AP-202647
Reported illnesses or injuries	None reported in the FDA notice
Status	Ongoing, per reporting published October 20, 2026

“Nationwide” describes where the products were distributed. The reported quantity is 23 vials, not millions of units.

Which Apothecary Pharma Tirzepatide Lots Are Recalled?

The product is Apothecary Pharma Tirzepatide Injection, 18 mg/mL, 4 mL sterile multidose vial, prescription only. Tirzepatide acts on both GIP and GLP-1 receptors. It is the active ingredient in Mounjaro and Zepbound, but this recalled product is a compounded formulation, not the FDA-approved brand.

All 22 Recalled Tirzepatide Lot Numbers and Beyond-Use Dates

Lot number	Beyond-use date (BUD)
AP-202622	October 7, 2026
AP-202623	October 8, 2026
AP-202624	October 19, 2026
AP-202625	October 20, 2026
AP-202627	October 26, 2026
AP-202628	October 27, 2026
AP-202629	October 28, 2026
AP-202630	October 31, 2026
AP-202631	November 1, 2026
AP-202632	November 3, 2026
AP-202633	November 7, 2026
AP-202634	November 8, 2026
AP-202635	November 16, 2026
AP-202636	November 17, 2026
AP-202637	November 18, 2026
AP-202638	November 19, 2026
AP-202639	November 20, 2026
AP-202640	November 21, 2026
AP-202641	November 22, 2026
AP-202642	November 24, 2026
AP-202643	November 25, 2026
AP-202644	November 26, 2026

Beyond-use dates across the tirzepatide lots run from October 7 to November 26, 2026. AP-202626 is not in the published list. Do not assume every number between AP-202622 and AP-202644 is recalled. Compare the lot printed on your vial with the list above.

What Does BUD Mean on a Compounded Vial?

BUD stands for beyond-use date, the date after which a compounded preparation should no longer be used. It is not the same as the expiration date on a mass-manufactured, FDA-approved drug. As of October 24, 2026, some BUDs above have already passed. A passed BUD does not make the recall irrelevant, because a recalled vial may still be in someone’s possession and should not be used.

The NDC identifies the product, but it does not replace checking the lot number. Treat a vial as affected only when the product and lot details match the recall.

Is the Apothecary Pharma NAD+ Injection Also Recalled?

Yes. One NAD+ vial was recalled for the same sterility reason.

Detail	Information
Product	Apothecary Pharma NAD+ Injection
Strength and size	200 mg/mL, 6 mL multidose vial
NDC	85091-011-06
Lot	AP-202647
Beyond-use date	October 13, 2026

NAD+ (nicotinamide adenine dinucleotide) is a molecule involved in cell metabolism. Injectable NAD+ is sometimes marketed for wellness uses. Do not skip checking this product just because most headlines focus on tirzepatide.

Does the Recall Include Mounjaro, Zepbound, Ozempic or Wegovy?

No. The recall notice does not list them. Tirzepatide is the active ingredient in Mounjaro and Zepbound, and semaglutide is the active ingredient in Ozempic and Wegovy. A compounded product can share an active ingredient with a brand-name drug without being the same manufactured product.

Product	In this recall?	Why
Apothecary Pharma Tirzepatide Injection, 18 mg/mL, listed lots	Yes	Named in the recall
Apothecary Pharma NAD+ Injection, lot AP-202647	Yes	Named in the recall
Mounjaro and Zepbound (Eli Lilly)	Not listed	FDA-approved branded tirzepatide
Ozempic and Wegovy (Novo Nordisk)	Not listed	FDA-approved branded semaglutide
Other pharmacies’ compounded tirzepatide	Not identified	The notice names only specific Apothecary Pharma lots

This does not mean every other compounded product is safe. It means only that this recall names the Apothecary Pharma lots above. Do not stop a separate, FDA-approved medication because of a headline. If you are unsure which formulation you have, ask your pharmacist or prescriber.

Why Was the Apothecary Pharma Injection Recalled?

The stated reason is a lack of assurance of sterility. Injectable drugs bypass some of the body’s natural barriers, so contamination can introduce microorganisms into tissue or the bloodstream.

The recall does not say that every vial was contaminated, name a specific bacterium or fungus, or prove that anyone became ill. It means the company could not assure that these vials met the sterility standard. A vial can look clear and still fail sterility requirements, so appearance is not a safe test.

Possible consequences of injecting a nonsterile product include a local infection, an abscess or, more rarely, a serious systemic infection. Risk depends on the type and amount of contamination and on the patient’s health. Multidose vials add concern because they are used repeatedly over time.

Have Any Illnesses Been Reported From the Recalled Injections?

The FDA notice and the reporting reviewed did not identify any illnesses or injuries linked to the recalled products. That describes what was public when the recall was announced. It is not a guarantee that no one was exposed.

What Does a Class II FDA Drug Recall Mean?

The FDA defines a Class II recall as one where use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse consequences is remote. It sits below Class I, where there is a reasonable probability of serious harm or death, and above Class III, where harm is unlikely.

Class II does not mean the product is safe to keep using. The classification reflects the FDA’s assessment of relative risk. Patients should follow the recall instructions and speak to their healthcare professional about their own situation.

What Should You Do If You Have a Recalled Apothecary Pharma Vial?

1. Check the label

Compare these details on your vial: manufacturer (Apothecary Pharma LLC), product name, strength and vial size, NDC, lot number and BUD. If your product does not match, do not assume it is covered. Ask your pharmacist to verify it.

2. Do not inject from a matching vial

Stop using it while you wait for instructions. If a dose is due soon, call your prescriber or pharmacist about a replacement or timing. Do not double up on a later dose unless your prescriber tells you to.

3. Contact your prescriber and dispensing pharmacy

If you got the medicine through a telehealth service, contact both the service and the pharmacy that dispensed it. The pharmacy can often identify your lot from its records. Apothecary Pharma notified recipients by letter.

4. Keep the vial and packaging for now

Store the vial away from children and pets, and keep the label and packaging. Ask the pharmacy how to return or dispose of it. The public reporting did not give a universal consumer return process. Put used needles and syringes in a sharps container.

5. If you already injected from an affected vial

Contact your healthcare professional even if you feel well, and give them the product name, lot number, injection date and any symptoms. Warning signs after an injection include:

• Fever or chills
• Increasing redness, warmth, swelling or pain at the injection site
• Pus or drainage from the site
• Feeling unusually unwell

Severe symptoms such as trouble breathing, confusion, fainting or rapidly worsening illness need emergency care. Exposure to a recalled vial does not mean an infection will develop.

6. Report a suspected adverse event

You or your clinician can report a problem through the FDA’s MedWatch program. A report does not prove the product caused the event, but it helps regulators evaluate safety concerns.

Why Did the FDA Send Apothecary Pharma a Warning Letter Before the Recall?

The FDA issued a warning letter to Apothecary Pharma dated December 1, 2025. It followed an inspection of the company’s Cary, North Carolina facility from May 12 to May 15, 2025, which found serious deficiencies in procedures for making drugs meant to be sterile. The letter cited issues including:

• Personnel practices that could disrupt clean airflow over exposed sterile containers
• Handling practices that could introduce contamination into critical areas
• Insufficient studies showing airflow stayed adequate during real production
• Equipment and surfaces that were hard to clean or visibly rusty
• Inadequate disinfection practices
• Gaps in written procedures, quality oversight and production records
• Deficiencies in some labeling and adverse-event reporting procedures

The FDA also noted that the company stopped sterile production on May 12, 2025, and said it intended to resume on August 1, 2025.

Does the 2025 Warning Letter Prove the Recalled Vials Were Contaminated?

No. The FDA has not linked the 2025 inspection findings to the vials in this 2026 recall. The recall’s stated basis is that sterility cannot be assured. The warning letter is important context, but it is a separate regulatory event. Read the FDA warning letter to Apothecary Pharma.

Why Are Compounded GLP-1 Drugs Under Scrutiny?

Compounding means preparing a medication by combining or altering ingredients for a specific patient need. Compounded drugs can serve legitimate medical purposes, but they are not individually reviewed by the FDA for safety, effectiveness and quality the way approved drugs are. Sterile injectables have to be made under strict contamination controls.

Demand for tirzepatide and semaglutide surged, and during earlier shortages compounders supplied alternatives. Once the FDA determined the shortages were resolved, the federal rules on compounding copies of approved drugs became more restrictive. Whether a given compounded product is lawful depends on the facts, including which statutory pathway applies. A product containing tirzepatide is not automatically unlawful, and this recall does not affect every compounding pharmacy.

For related reading on enforcement against other compounders, see Empower Pharmacy Lawsuit, FDA Warning Letters, Eli Lilly Battle, $700M Legal Storm Hitting Compound Pharmacies. That case involves a different company and products. For separate litigation over approved GLP-1 drugs, see Ozempic Vision Loss Lawsuit, Claims, MDL Status & Eligibility and Weight Loss Drug Lawsuits 2026, FDA Warnings And New Vision Loss And GI Injury Claims January 2026 Update. Those matters involve separate legal issues and do not show that the recalled Apothecary Pharma vials caused the injuries alleged there.

Is There a Lawsuit or Settlement Over the Apothecary Pharma Recall?

As of October 24, 2026, no lawsuit, settlement, compensation program or claim form tied to this recall was identified in the sources reviewed. A recall is a safety and regulatory action, not a settlement, and it does not by itself create a right to payment.

Whether a legal claim exists depends on the facts, proof of injury, causation and applicable law. If you believe you were harmed, get medical care first, keep your records, pharmacy receipts, labels and recall communications, and consult a qualified attorney about your individual situation. Do not pay any website that promises a guaranteed recall payout when no official claim process exists.

Frequently Asked Questions

Which GLP-1 injections did Apothecary Pharma recall?

Apothecary Pharma recalled 22 vials of compounded Tirzepatide Injection, 18 mg/mL, 4 mL multidose vials, NDC 85091-001-18. The lots are AP-202622 through AP-202625 and AP-202627 through AP-202644.

Is the Apothecary Pharma NAD+ injection recalled too?

Yes. One vial of NAD+ Injection, 200 mg/mL, 6 mL multidose vial, NDC 85091-011-06, lot AP-202647, is included. It is not a GLP-1 drug.

Are Mounjaro and Zepbound part of the Apothecary Pharma recall?

No. The notice does not list them. They are FDA-approved branded products, while the recalled item is a compounded tirzepatide vial from Apothecary Pharma.

Are Ozempic and Wegovy part of the Apothecary Pharma recall?

No. They contain semaglutide and are not named in this recall.

Why did Apothecary Pharma recall the injections?

Sterility of the specified vials could not be assured. The public information does not say every vial was contaminated or name a specific contaminant.

What does a Class II recall mean for the Apothecary Pharma injections?

The FDA classified it on October 8, 2026, meaning use may cause temporary or medically reversible health effects, or serious effects are remote. It still requires following the recall instructions.

When did the Apothecary Pharma recall begin?

The company started the voluntary recall on September 24, 2026, and the FDA classified it Class II on October 8, 2026.

How many vials did Apothecary Pharma recall?

Twenty-three vials in total: 22 tirzepatide and 1 NAD+.

Have any illnesses been reported from the recalled Apothecary Pharma vials?

None were reported in the FDA notice or in the reporting reviewed as of October 24, 2026.

What should I do if my vial matches a recalled Apothecary Pharma lot?

Do not inject from it. Contact your prescriber and dispensing pharmacy about a replacement and about returning or disposing of the vial.

What if I already used a recalled Apothecary Pharma injection?

Contact your healthcare professional with the product and lot details. Seek care promptly for fever, chills, or increasing redness, swelling or pain at the injection site. Severe symptoms need emergency care.

Is all compounded tirzepatide recalled?

No. Only the Apothecary Pharma lots and the one NAD+ vial listed above are named in this recall.

Can I get a refund or file a claim over the Apothecary Pharma recall?

No public claim form or compensation program was identified. Ask the dispensing pharmacy about returns, replacements or refunds.

Bottom Line

Apothecary Pharma recalled 22 vials of compounded tirzepatide (NDC 85091-001-18, lots AP-202622 to AP-202625 and AP-202627 to AP-202644) and one NAD+ vial (NDC 85091-011-06, lot AP-202647) because sterility cannot be assured. The FDA classified the recall as Class II on October 8, 2026. Mounjaro, Zepbound, Ozempic and Wegovy are not named. If your vial matches, do not use it until your prescriber or pharmacist advises you, and seek medical advice if you notice signs of infection.

Sources and Verification

1. FDA Enforcement Report, Apothecary Pharma Recall, Event 99952
2. FDA Warning Letter to Apothecary Pharma LLC, December 1, 2025
3. FDA, Understanding Drug Recalls: What to Know and What to Do
4. FDA, Recall Background and Definitions
5. FDA, Compounding: Inspections, Recalls and Other Actions
6. FDA MedWatch, Report an Adverse Event
7. FOX Business, GLP-1 Injections Recalled Nationwide Over Sterility Concerns, October 20, 2026
8. Becker’s Hospital Review, Compounded GLP-1 Injections Recalled Nationwide, October 20, 2026

Disclaimer: This article is general information, not medical or legal advice. AllAboutLawyer.com is a legal information website, not a law firm. Follow the instructions of the FDA, the recalling company, your pharmacist and your healthcare professional.

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the FDA enforcement report, the FDA warning letter and FDA recall guidance, and cross-checked with published reporting on the FDA notice, as of October 24, 2026. Last Updated: October 24, 2026.